Despite the traditional notion that nothing therapeutic can be accomplished for the 1.5 million Americans with autism and the 2 million more throughout the world, there are pharmacologic approaches to the disease that are providing some help for patients and garnering revenues for drug companies.
This Market Briefing reviews the market for drugs used in the treatment of autism and related disorers, including Antidepressants, Anti-Anxiety drugs, Anti-psychotics, Anti-convulsants, and CNS stimulants for ADHD-related symptoms, forecasting revenues through 2009 gloabally and in the biggest three national markets.
In addition, a variety of new approaches to the treatment of autism are moving through the development pipeline. Research in genomics, metabolomics, and systems biology are all being applied to the development of therapeutics, and there have been notable successes and notable failures in clinical development. The report reviews progress toward commercialization in this nascent field, and forecasts market potential and various market scenerios.